Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma

Despite intensive treatment, including consolidation immunotherapy (IT), prognosis of high-risk neuroblastoma (HR-NBL) is poor. Immune status of patients over the course of treatment, and thus immunological features potentially explaining therapy efficacy, are largely unknown. In this study, the dyn...

Full description

Bibliographic Details
Main Authors: Celina L. Szanto, Annelisa M. Cornel, Sara M. Tamminga, Eveline M. Delemarre, Coco C. H. de Koning, Denise A. M. H. van den Beemt, Ester Dunnebach, Michelle L. Tas, Miranda P. Dierselhuis, Lieve G. A. M. Tytgat, Max M. van Noesel, Kathelijne C. J. M. Kraal, Jaap-Jan Boelens, Alwin D. R. Huitema, Stefan Nierkens
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
neuroblastoma
immune monitoring
anti-GD2
IL-2
GM-CSF
ASCT
Online Access:https://www.mdpi.com/2072-6694/13/9/2096

Internet

https://www.mdpi.com/2072-6694/13/9/2096

Similar Items